<DOC>
	<DOCNO>NCT01660802</DOCNO>
	<brief_summary>This study ass safety efficacy 700 Î¼g dexamethasone Posterior Segment Drug Delivery System ( DEX PS DDS ) Applicator System patient macular edema 6 month double-blind period versus sham follow 2 month open label period .</brief_summary>
	<brief_title>Safety Efficacy Study Dexamethasone Treatment Patients With Macular Edema Following Retinal Vein Occlusion ( RVO )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Presence macular edema define macular thicken involve center macula due branch retinal vein occlusion ( BRVO ) central retinal vein occlusion ( CRVO ) History glaucoma , ocular hypertension optic nerve head change Any active bacterial , viral , parasitic , fungal infection either eye Eye surgery , include cataract surgery , and/or laser type study eye within 3 month prior study start History use intravitreal steroid intravitreal injectable drug study eye within 3 month prior study start Use oral , intravenous , intramuscular , epidural , rectal , extensive dermal steroid within 1 month prior study start Use immunosuppressant , immunomodulators , antimetabolite , and/or alkylating agent within 3 month prior study start Use topical ophthalmic corticosticosteroids within 2 week study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>